Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

Harrow Inc. 03 mg from Viatris Inc. (NASDAQ: VTRS ). , China, and Taiwan, with marketing authorization applications pending in other countries.

Harrow will pay $30 million in cash and up to $70 million in contingent milestone payments tied to Tyrvaya’s net sales, for a potential total consideration of up to $100 million. The transaction is expected to close in the second half of 2026. Read Also: RFK Jr. Wants Fewer Americans On Antidepressants — Here's Why The Debate Is Exploding Viatris Q2 Performance Viatris on Thursday reported second-quarter adjusted earnings of 69 cents per share, beating the consensus of 60 cents.

675 billion. 5% on an operational basis), primarily driven by new product sales in Developed Markets and strong growth in Greater China. “Our second-quarter results reflect another quarter of strong execution and reinforce the momentum we’re building across our business,” said Scott A. Smith, CEO, Viatris.

” In the company earnings conference call, Viatris said the Tyrvaya deal will help it focus on high-potential growth areas, particularly in complex generics and transdermal products, as well as continued investment in the Greater China market. Viatris Raises 2026 Earnings And Sales Guidance “Our strong first-half results give us the confidence to raise our full-year guidance. We expect a more balanced operating environment in the second half of the year, and we remain focused on disciplined execution, investing behind our future growth drivers and creating long-term value for patients and shareholders,” Smith said. 44.

783 billion. 91 at the time of publication on Thursday, according to Pro data. Read Also: SpaceX, Tesla Confirm Terafab Site as Chip Demand Outruns Global Supply Image via Shutterstock